Comparative Pharmacology
Head-to-head clinical analysis: TRIAVIL 2 25 versus TRIAVIL 4 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIAVIL 2 25 versus TRIAVIL 4 50.
TRIAVIL 2-25 vs TRIAVIL 4-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRIAVIL 2-25 contains perphenazine and amitriptyline. Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, reducing dopaminergic neurotransmission. It also has alpha-adrenergic and anticholinergic effects. Amitriptyline is a tricyclic antidepressant that inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, muscarinic, and alpha-adrenergic receptors.
Amitriptyline is a tricyclic antidepressant that inhibits reuptake of serotonin and norepinephrine. Perphenazine is a typical antipsychotic that blocks dopamine D2 receptors.
One tablet (2 mg perphenazine / 25 mg amitriptyline) orally 3 to 4 times daily; maintenance dose: 2 to 4 tablets daily.
One tablet (4 mg perphenazine / 50 mg amitriptyline) orally three times daily to four times daily. Maximum: 8 tablets per day.
None Documented
None Documented
Amitriptyline: 9-25 hours (mean 15 hours); perphenazine: 9-12 hours. Steady-state achieved in 3-7 days.
Amitriptyline: 15-40 hours (mean 20-30 hours); perphenazine: 9-12 hours; clinical context: steady-state achieved within 5-7 days, dosing adjustments needed in hepatic impairment.
Primarily renal (approximately 70-80% as metabolites, <5% unchanged for amitriptyline; perphenazine excreted renally and fecally).
Renal: 50-60% as metabolites (amitriptyline and perphenazine), <5% unchanged; fecal: 20-30% (primarily perphenazine metabolites); biliary: minor route for perphenazine.
Category C
Category C
Antidepressant-Antipsychotic Combination
Antidepressant-Antipsychotic Combination